K. Papp

发表

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

A. Nakanishi, K. Papp, M. Lahfa, 2005, The British journal of dermatology.

Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies

A. Bitton, Deepali Kumar, S. Jamal, 2018, Journal of cutaneous medicine and surgery.

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study

A. Menter, E. Edson-Heredia, K. Reich, 2019, The British journal of dermatology.

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

M. Gooderham, K. Papp, K. Reich, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28

S. Green, M. Gooderham, K. Papp, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials

A. Kimball, S. Green, M. Gooderham, 2018, The British journal of dermatology.

Impact of adalimumab treatment on health‐related quality of life and other patient‐reported outcomes: results from a 16‐week randomized controlled trial in patients with moderate to severe plaque psoriasis

J. Saurat, J. Ortonne, K. Papp, 2007, The British journal of dermatology.

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate‐to‐severe psoriasis: a randomized controlled trial

F. Nestle, J. Ortonne, K. Papp, 2006, The British journal of dermatology.

Open‐label study of etanercept treatment in patients with moderate‐to‐severe plaque psoriasis who lost a satisfactory response to adalimumab

D. Collier, S. Tyring, G. Kricorian, 2017, The British journal of dermatology.

AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis

Pantelis K. Vlachos, P. Vlachos, K. Papp, 2019, The British journal of dermatology.

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial†

Kelly N. Taylor, Constance M. Brown, B. Elewski, 2019, The British journal of dermatology.